

NAME	Tarceva (Erlotinib)
STRENGTH	50mg
FORM	Tablet
SCHEDULE	4
INGREDIENTS	
Tarceva 100mg tablets	
METHOD	Break the tablet using a dedicated chemotherapy tablet cutter, the tablets are NOT scored, breaking using other means is not advised. Do not use this tablet cutter for any other non- chemotherapy type of tablet, and clean thoroughly between each use.
STORAGE & OTHER INSTRUCTIONS	Do not break all the tablets at the start of a month for the entire pack, as some of these halves will only be used in nearly two months time. Break each tablet as required. Only the patient should handle this medication, or their caregiver with appropriate PPE (single use gloves).
LABEL Example	Take one broken (half) tablet daily, one hour before or two hours after meals.
EXPIRY	NA – whole tablets will have expiry on main package, broken tablets should be used within two days
Author	Tegan Bilse, Johan Labuschagne (pharmacist on case)

*Special notes: This formulation document is based on a case study from a South African practice. The conclusion was based on research and data obtained from Roche. The half life of Tarceva is 36 hours, and hence a 48 hourly dose of 100mg instead of 50mg daily was not considered as optimal treatment.

The enteric coating on the tablets is not to protect it from gastric environments, rather to prevent an unpleasant taste for the patient.

REFERENCES: Available from involved pharmacists on request –

[GSR] [TSR] Film-Coating of Tarceva Tablets.pdf

[Literature Search] Erlotinib – dosing every other day in lung cancer.pdf

Roche-MI-Response-2020-06-23-08-32.pdf

Usage of this formulation must be discussed with the treating Physician of the patient. The user will absolve SASOPh and its directors, Board and author from all liability and indemnified them for any claim instituted by any person for damages or loss of whatsoever nature (including consequential damages or special damages of any nature) following directly or indirectly from any injury (including fatal injury) suffered by or damages caused to the patient or any illness (including terminal illness) contracted by the patient, whatever the cause was with the exclusion of the intentional omission by SASOPh, its Directors, Board and members.